Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Agency (2)
- Antitrust and Trade Regulation (2)
- Business Organizations Law (2)
- Criminal Law (2)
- Criminal Procedure (2)
-
- Environmental Law (2)
- Food and Drug Law (2)
- Health Law and Policy (2)
- Intellectual Property Law (2)
- Labor and Employment Law (2)
- Law and Economics (2)
- Law and Society (2)
- Legal Profession (2)
- Organizations Law (2)
- Torts (2)
- Accounting Law (1)
- Admiralty (1)
- Agriculture Law (1)
- Air and Space Law (1)
- Animal Law (1)
- Banking and Finance Law (1)
- Bankruptcy Law (1)
- Civil Law (1)
- Civil Rights and Discrimination (1)
- Commercial Law (1)
- Communications Law (1)
- Comparative and Foreign Law (1)
- Computer Law (1)
- Institution
- Publication
- Publication Type
Articles 1 - 3 of 3
Full-Text Articles in Administrative Law
Breaking The Bank: Revisiting Central Bank Of Denver After Enron And Sarbanes-Oxley, Celia Taylor
Breaking The Bank: Revisiting Central Bank Of Denver After Enron And Sarbanes-Oxley, Celia Taylor
ExpressO
No abstract provided.
Organizational Misconduct: Beyond The Principal-Agent Model, Kimberly D. Krawiec
Organizational Misconduct: Beyond The Principal-Agent Model, Kimberly D. Krawiec
ExpressO
This article demonstrates that, at least since the adoption of the Organizational Sentencing Guidelines in 1991, the United States legal regime has been moving away from a system of strict vicarious liability toward a system of duty-based organizational liability. Under this system, organizational liability for agent misconduct is dependant on whether or not the organization has exercised due care to avoid the harm in question, rather than under traditional agency principles of respondeat superior. Courts and agencies typically evaluate the level of care exercised by the organization by inquiring whether the organization had in place internal compliance structures ostensibly designed …
The Problem Of New Uses, Rebecca S. Eisenberg
The Problem Of New Uses, Rebecca S. Eisenberg
Articles
Discovering new uses for drugs that are already on the market seems like it ought to be the low-lying fruit of biopharmaceutical research and development (R&D). Firms have already made significant investments in developing these drugs and bringing them to market, including testing them in clinical trials, shepherding them through the FDA regulatory approval process, building production facilities, and training sales staff to market them to physicians. By this point, the drugs have begun to enjoy goodwill among patients and physicians and casual observations in the course of clinical experience may point to potential new uses. One might expect that …